Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the DipThe Motley Fool • 12/16/23
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of MedicineInvestors Business Daily • 12/12/23
After Golden Cross, CRISPR Therapeutics AG (CRSP)'s Technical Outlook is BrightZacks Investment Research • 12/11/23
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?The Motley Fool • 12/11/23
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per personBusiness Insider • 12/09/23
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is NonplussedSeeking Alpha • 12/09/23
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in USInvestopedia • 12/08/23
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell DiseaseBusiness Wire • 12/08/23
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatmentMarket Watch • 12/08/23
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing TreatmentInvestors Business Daily • 12/08/23